Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief...
-
– Odevixibat verfügt über das Potenzial, das erste zugelassene Arzneimittel für die Behandlung aller Formen von PFIC zu werden – – Die Beurteilung des CHMP basiert auf den PEDFIC-Phase-3-Studien – ...
-
– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus...
-
- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC - - Data showing long-term treatment benefits of...
-
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
-
– BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU– – Completed global commercial agreements for two key top ten markets – – ASSERT & BOLD Phase 3...
-
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
-
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug...
-
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in...
-
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing...